{"id":1057,"date":"2025-07-19T23:16:07","date_gmt":"2025-07-19T23:16:07","guid":{"rendered":"https:\/\/mediwhale.stage.studio-jt.co.kr\/kr\/?post_type=publication&#038;p=1057"},"modified":"2025-07-19T23:16:07","modified_gmt":"2025-07-19T23:16:07","slug":"deep-learning-based-cardiovascular-risk-stratification-for-stage-1-hypertension-using-retinal-photographs","status":"publish","type":"publication","link":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/publication\/deep-learning-based-cardiovascular-risk-stratification-for-stage-1-hypertension-using-retinal-photographs\/","title":{"rendered":"Deep learning-based cardiovascular risk stratification for stage 1 hypertension using retinal photographs"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Abstract<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Purpose<\/strong><\/h4>\n\n\n\n<p>The advent of deep learning (DL) algorithms has now made it possible to predict the risk of cardiovascular disease (CVD) using retinal images. We had previously developed a retina-based DL model, Reti-CVD, which successfully predicted future CVD incidents in a longitudinal study. According to US guidelines, adults with stage 1 hypertension (HTN) who have an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 10% or higher should be managed initially with blood pressure (BP) lowering medication. This study aims to investigate to use Reti-CVD score for decisions on BP-lowering medication among adults with stage 1 HTN.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Methods\u00a0<\/strong><\/h4>\n\n\n\n<p>Our study included 7664 adults with stage 1 HTN from the UK Biobank. Reti-CVD scores were calculated and categorized into two risk groups \u2013 low (n=6433), and high (n=1231), based on the same number of participants with 0 to 10% and \u226510% 10-year ASCVD risk according to Pooled Cohort Equation (PCE). To assess the Reti-CVD\u2019s ability to predict fatal and non-fatal CVD events, we performed a survival analysis on the longitudinal data using Cox proportional-hazards models and hazard ratios (HRs).<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Results\u00a0<\/strong><\/h4>\n\n\n\n<p>Among the 7664 participants with stage 1 HTN, 125 (1.6%) had nonfatal and fatal ASCVD events during the 10-year follow-up. Based on the standard of care (PCE), those with \u226510% ASCVD risk group (4.5 CVD incidence rate per 1000 person-years[IR]) showed significantly increased risk of ASCVD events (HR=3.87, 95%CI:2.71-5.53) compared with &lt;10% ASCVD risk group (1.2-CVD IR). In comparison to the low-risk group (1.2-CVD IR), the high-risk group (4.2-CVD IR) of Reti-CVD was significantly associated with increased risk of ASCVD events (HR=3.48, 95%CI: 2.43-4.99) in the multivariable Cox model. The two-tier Reti-CVD (low- vs high-risk) showed prognostic performance with a concordance index of 0.620 (95%CI:0.577-0.663).<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Conclusions\u00a0<\/strong><\/h4>\n\n\n\n<p>With DL, retinal photographs could be used as a surrogate marker for cardiovascular risk stratification for stage 1 HTN given its compatibility with the estimated 10-year ASCVD risk predictions from blood tests. Our findings suggest that contactless and non-invasive retinal photography may be adopted as a supportive and adjunctive modality to aid decision-making in starting BP-lowering medication for adults with stage 1 HTN, especially, patients who fail to meet the &lt;130\/80 mmHg treatment goal even after nonpharmacologic therapy.<\/p>\n\n\n\n<p>This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.<\/p>\n","protected":false},"template":"","publication_type_categories":[12],"publication_categories":[16],"class_list":["post-1057","publication","type-publication","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication\/1057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/types\/publication"}],"version-history":[{"count":1,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication\/1057\/revisions"}],"predecessor-version":[{"id":1058,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication\/1057\/revisions\/1058"}],"wp:attachment":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/media?parent=1057"}],"wp:term":[{"taxonomy":"publication_type_categories","embeddable":true,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication_type_categories?post=1057"},{"taxonomy":"publication_categories","embeddable":true,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication_categories?post=1057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}